Preclinical support for tumor protein D52 as a cancer vaccine antigen
ABSTRACTOverexpressed tumor-associated antigens (TAAs) are a large group that includes proteins found at increased levels in tumors compared to healthy cells. Universal tumor expression can be defined as overexpression in all cancers examined as has been shown for Tumor Protein D52. TPD52 is an over...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2273699 |
| _version_ | 1797354187699257344 |
|---|---|
| author | Robert K. Bright |
| author_facet | Robert K. Bright |
| author_sort | Robert K. Bright |
| collection | DOAJ |
| description | ABSTRACTOverexpressed tumor-associated antigens (TAAs) are a large group that includes proteins found at increased levels in tumors compared to healthy cells. Universal tumor expression can be defined as overexpression in all cancers examined as has been shown for Tumor Protein D52. TPD52 is an over expressed TAA actively involved in transformation, leading to increased proliferation and metastasis. TPD52 overexpression has been demonstrated in many human adult and pediatric malignancies. The murine orthologue of TPD52 (mD52) parallels normal tissue expression patterns and known functions of human TPD52 (hD52). Here in we present our preclinical studies over the past 15 years which have demonstrated that vaccine induced immunity against mD52 is effective against multiple cancers in murine models, without inducing autoimmunity against healthy tissues and cells. |
| first_indexed | 2024-03-08T13:46:49Z |
| format | Article |
| id | doaj.art-e3ae3616fe0541bb9eaa1bdea471b023 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-08T13:46:49Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-e3ae3616fe0541bb9eaa1bdea471b0232024-01-16T09:00:10ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-12-0119310.1080/21645515.2023.2273699Preclinical support for tumor protein D52 as a cancer vaccine antigenRobert K. Bright0Department of Immunology and Molecular Microbiology, School of Medicine and Cancer Center, Texas Tech University Health Sciences Center, Lubbock, TX, USAABSTRACTOverexpressed tumor-associated antigens (TAAs) are a large group that includes proteins found at increased levels in tumors compared to healthy cells. Universal tumor expression can be defined as overexpression in all cancers examined as has been shown for Tumor Protein D52. TPD52 is an over expressed TAA actively involved in transformation, leading to increased proliferation and metastasis. TPD52 overexpression has been demonstrated in many human adult and pediatric malignancies. The murine orthologue of TPD52 (mD52) parallels normal tissue expression patterns and known functions of human TPD52 (hD52). Here in we present our preclinical studies over the past 15 years which have demonstrated that vaccine induced immunity against mD52 is effective against multiple cancers in murine models, without inducing autoimmunity against healthy tissues and cells.https://www.tandfonline.com/doi/10.1080/21645515.2023.2273699TPD52 (D52)mD52 (murine orthologue TPD52)hD52 (human orthologue TPD52)overexpressed tumor-self antigenoncogenicshared |
| spellingShingle | Robert K. Bright Preclinical support for tumor protein D52 as a cancer vaccine antigen Human Vaccines & Immunotherapeutics TPD52 (D52) mD52 (murine orthologue TPD52) hD52 (human orthologue TPD52) overexpressed tumor-self antigen oncogenic shared |
| title | Preclinical support for tumor protein D52 as a cancer vaccine antigen |
| title_full | Preclinical support for tumor protein D52 as a cancer vaccine antigen |
| title_fullStr | Preclinical support for tumor protein D52 as a cancer vaccine antigen |
| title_full_unstemmed | Preclinical support for tumor protein D52 as a cancer vaccine antigen |
| title_short | Preclinical support for tumor protein D52 as a cancer vaccine antigen |
| title_sort | preclinical support for tumor protein d52 as a cancer vaccine antigen |
| topic | TPD52 (D52) mD52 (murine orthologue TPD52) hD52 (human orthologue TPD52) overexpressed tumor-self antigen oncogenic shared |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2023.2273699 |
| work_keys_str_mv | AT robertkbright preclinicalsupportfortumorproteind52asacancervaccineantigen |